Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
Since the companyâs inception, Tetraphase has developed a robust antibiotics pla...
Since the companyâs inception, Tetraphase has...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is ...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.